Secondary Cutaneous Amyloidosis in a Patient with Mycosis Fungoides

Nam, Chan Hee; Park, Min Kee; Choi, Mi Soo; Hong, Soon-Tae; Park, Byung Cheol; Kim, Myung Hwa

doi:10.5021/ad.2017.29.1.79

Cited by 3 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SLCA may also be associated with local, chronic inflammatory conditions that may also induce apoptotic processes (4,5). It is hypothesized that "drop off" of epidermal keratinocytes into the dermis and the interaction between epidermal components and fibroblasts are essential for the formation of amyloid precursors (3).…”

Section: Discussionmentioning

confidence: 99%

“…In these series, the solid, adenoid and cystic types of BCC were found to be more commonly associated with SLCA (6). Additionally, a rarer association without a clinical significance of SLCA with other skin conditions like disseminated superficial actinic porokeratosis, melanocytic nevi, mycosis fungoides, PUVA-exposed skin, discoid lupus erythematosus, and dermatofibroma has also been reported (1,4,5).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Secondary localized cutaneous amyloidosis is not rare in bowenÂ’s disease and bowenoid papulosis

Baykal¹,

Hurdogan²,

Kobaner³

et al. 2021

TJPATH

View full text Add to dashboard Cite

Secondary localized cutaneous amyloidosis is a histopathological finding seen in the dermis, in various benign, premalignant, and malignant skin conditions, without clinical significance. The real incidence is not known. We aimed to investigate the phenomenon of secondary localized cutaneous amyloidosis in Bowen's disease and Bowenoid papulosis. We retrospectively evaluated the data of all cases with histopathological confirmation of Bowen's disease and Bowenoid papulosis between 2006 and 2017 in our Dermatovenereology and/or Pathology departments. Secondary localized cutaneous amyloidosis was observed in three patients with Bowen's disease (3/52; 5.8%) and in three patients with Bowenoid papulosis (3/18; 16.7%). Herein, we present the demographic, clinical and histopathological features of these six cases of secondary localized cutaneous amyloidosis in detail. Although the occurrence of secondary localized cutaneous amyloidosis in epithelial tumors is a well-known phenomenon, its incidence has not been previously reported in Bowen's disease and Bowenoid papulosis. Therefore, our results indicating a high incidence may be particularly important for Bowenoid papulosis, as its association with secondary localized cutaneous amyloidosis has only been shown in one case before. Moreover, in three of six cases, we histologically observed areas of regression with a marked prominence of amyloid deposition. Remarkably, two of these patients had a history of topical application of destructive agents which reveals a possible etiologic relationship between secondary localized cutaneous amyloidosis and cellular apoptosis/necrosis induced by these external agents.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Secondary localized cutaneous amyloidosis is not rare in bowenÂ’s disease and bowenoid papulosis

Baykal¹,

Hurdogan²,

Kobaner³

et al. 2021

TJPATH

View full text Add to dashboard Cite

show abstract

“…AL amyloidosis protein—from the deposition of immunoglobulin light chain fragments—occurs in patients with multiple myeloma and cutaneous nodular amyloidosis. In contrast, the deposition of AA amyloidosis protein—derived from keratinocytes—can be observed in patients with chronic inflammatory conditions and cutaneous lichenoid and macular amyloidosis [ 9 , 19 - 20 ].…”

Section: Discussionmentioning

confidence: 99%

“…Benign conditions and skin neoplasms, in addition to premalignant lesions, which have been associated with secondary amyloidosis include actinic keratosis, cylindroma, fibroma, melanocytic nevi, pilomatricoma, porokeratosis (disseminated superficial actinic and Mibelli), PUVA (psoralen and ultraviolet A)-treated skin, sebaceous gland hyperplasia, seborrheic keratosis, solar elastosis, and syringocystadenoma. In addition to basal cell carcinoma, secondary cutaneous amyloid deposition has been observed in the cancer lesions of patients with in situ and invasive squamous cell carcinoma, Merkel cell carcinoma, and mycosis fungoides [ 3 , 7 - 9 , 13 , 15 - 16 , 19 ].…”

Section: Discussionmentioning

confidence: 99%

Basal Cell Carcinoma Associated with Secondary Localized Cutaneous Amyloid Deposits: Case Report and Review

Cohen¹

2019

Cureus

View full text Add to dashboard Cite

Amyloid deposition has been observed in tissue specimens of basal cell carcinomas. A 68-year-old man with a nodular basal cell carcinoma on his left arm near the elbow is described; microscopic evaluation of the biopsy tissue specimen shows not only nodular aggregates and strands of atypical basaloid tumor cells but also marked deposition of amorphous amyloid material in the stroma between the aggregates of basal cell carcinoma. Including the man in this report, there are additional individual descriptions of patients whose basal cell carcinomas have amyloid deposits in the adjacent stroma or within the tumor aggregates or both. In addition, several retrospective pathology investigations have evaluated the features of this phenomenon. The incidence of basal cell carcinoma with amyloid deposition, in the English literature, ranges from 11% to 75%; however, it is possible that staining technique or tumor subtype or quantity of amyloid present may account for the lower detection of amyloid observed by some of the researchers. Amyloid in basal cell carcinoma specimens was observed to be present more frequently in older patients who had tumors with less aggressive histology patterns. Nodular basal cell carcinoma was the most common subtype of tumor with amyloid deposits whereas superficial basal cell carcinoma was the least frequent subtype. The amyloid deposits were usually identified on hematoxylin and eosin-stained sections and confirmed by using stains that allowed for easier visualization of the amyloid. The amyloid deposits were most commonly located in the stroma between the tumor aggregates; other locations included the papillary dermis above the carcinoma, the dermis at the advancing edge of the tumor and within the aggregates of basal cell carcinoma. Many of the basal cell carcinomas with amyloid deposits, similar to the reported patient, also contained solar elastosis. The origin of the amyloid deposition in these tumors is secondary amyloid AA protein from keratin derived from the epithelial cells overlying the basal cell carcinomas. The presence of amyloid deposition does not alter the management of these basal cell carcinomas; the treatment of the tumor is the same as when the basal cell carcinoma does not contain amyloid deposition.

show abstract

Integrated Network-Based Analysis of Diseases Associated with Amyloid Deposition Through a Disease–Protein–Drug Network

Rizou,

Nasi,

Apostolakou

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Background: At present, the complexity that governs the associations between different biological entities is understood better than ever before, owing to high-throughput techniques and systems biology. Networks of interactions are necessary not only for the visualization of these complex relationships but also because their analysis tends to be valuable for the extraction of novel biological knowledge. Methods: For this reason, we constructed a disease–protein–drug network, focusing on a category of rare protein-misfolding diseases, known as amyloidoses, and on other pathological conditions also associated with amyloid deposition. Apart from the amyloidogenic proteins that self-assemble into fibrils, we also included other co-deposited proteins found in amyloid deposits. Results: In this work, protein–protein, protein–drug, and disease–drug associations were collected to create a heterogenous network. Through disease-based and drug-based analyses, we highlighted commonalities between diseases and proposed an approved drug with prospects of repurposing. Conclusions: The identified disease associations and drug candidates are proposed for further study that will potentially help treat diseases associated with amyloid deposition.

show abstract

Secondary Cutaneous Amyloidosis in a Patient with Mycosis Fungoides

Cited by 3 publications

References 15 publications

Secondary localized cutaneous amyloidosis is not rare in bowenÂ’s disease and bowenoid papulosis

Secondary localized cutaneous amyloidosis is not rare in bowenÂ’s disease and bowenoid papulosis

Basal Cell Carcinoma Associated with Secondary Localized Cutaneous Amyloid Deposits: Case Report and Review

Integrated Network-Based Analysis of Diseases Associated with Amyloid Deposition Through a Disease–Protein–Drug Network

Contact Info

Product

Resources

About